Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2020
NICE pushes Doptelet for pre-surgery liver disease treatment
5 March 2020 - NICE has published a new final draft guidance recommending Dova Pharmaceuticals’ Doptelet (avatrombopag) for thrombocytopenia - ...
Posted by Michael Wonder on 03 Mar 2020
Strategic collaboration announced by NICE and Health Technology Wales
3 March 2020 - Collaboration outlines the strategic planning and delivery of independent and authoritative medical technology guidance. ...
Posted by Michael Wonder on 02 Mar 2020
U.K. sets red lines on drug prices, food in U.S. trade talks
2 March 2020 - Johnson’s government publishes goals for negotiations. ...
Posted by Michael Wonder on 27 Feb 2020
NICE recommends new ‘chemotherapy-free’ treatment for lymphoma
27 February 2020 - A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been ...
Posted by Michael Wonder on 26 Feb 2020
UK NICE to announce decision on Vertex’s therapy Trikafta in December
26 February 2020 - NICE is currently in the process of evaluating Vertex Pharmaceuticals’ triple combination therapy — known as ...
Posted by Michael Wonder on 26 Feb 2020
Polivy struck by NICE ‘no’
26 February 2020 - The National Institute for Health and Care Excellence has announced that it does not recommend Polivy ...
Posted by Michael Wonder on 22 Feb 2020
UK deal over inclisiran
18 February 2020 - Government’s public enthusiasm looks premature given the lack of available data ...
Posted by Michael Wonder on 22 Feb 2020
Health ministers condemn Novartis lottery for Zolgensma, the world’s most expensive drug
12 February 2020 - Novartis has held the first draw to choose four babies who will receive its one-shot treatment ...
Posted by Michael Wonder on 12 Feb 2020
Researchers wanted to study the public’s views of health-related quality of life
12 February 2020 - Applications close on Wednesday 4 March 2020 ...
Posted by Michael Wonder on 12 Feb 2020
NICE refuses Keytruda, Inlyta cancer combo
12 February 2020 - NICE has released a draft guidance rejecting MSD’s Keytruda (pembrolizumab) when used in combo with Pfizer’s ...
Posted by Michael Wonder on 05 Feb 2020
NICE plans to widen the net for data it uses in guidance
5 February 2020 - UK cost-effectiveness body NICE has said it intends to use a broader range of data and ...
Posted by Michael Wonder on 04 Feb 2020
Broader types of data to be used in development of NICE guidance
4 February 2020 - An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact ...
Posted by Michael Wonder on 04 Feb 2020
Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
4 February 2020 - NICE has today published the outcome of the appeal against its final draft guidance on erenumab (Aimovig; ...
Posted by Michael Wonder on 03 Feb 2020
Rinvoq NICE approval could benefit 54,000 people
3 February 2020 - The National Institute for Health and Care Excellence has announced a new draft guidance recommending Abbvie’s ...
Posted by Michael Wonder on 30 Jan 2020
Brexit D-Day
31 January 2020 - After more than three years of Brexit talks, deals and political wrangling, the United Kingdom will officially ...